Norwegian Cruise Line Holdings Ltd. has announced that its guests will no longer have to complete pre-embarkation COVID-19 testing unless required by local regulations. This policy will go into effect across Norwegian Cruise Line, Oceania Cruises and Regent Seven Seas Cruises starting August 1, 2022.
However, the pre-cruise testing requirement will remain in place for guests currently traveling on voyages departing from destinations with local testing regulations, including but not limited to the U.S., Canada, Greece and Bermuda. The relaxation of the testing policy is aligned with the rest of the travel, leisure and hospitality industry worldwide as society continues to adapt and return to a state of normalcy. The company continues to encourage guests to follow vaccination protocols and test at their convenience prior to travel.
All voyages across the company’s three brands continue to operate under its science-backed SailSAFE health and safety program which will evolve along with the public health environment. Norwegian Cruise Line Holdings Ltd. also follows applicable local protocols at the ports and destinations it visits.
Norwegian Cruise Line Holdings Ltd. operates the Norwegian Cruise Line, Oceania Cruises and Regent Seven Seas Cruises brands. With a combined fleet of 28 ships with approximately 60,000 berths, these brands offer itineraries to more than 490 destinations worldwide. The company has nine additional ships scheduled for delivery through 2027, comprising approximately 24,000 berths.
For more information, visit www.nclhltd.com.
Related Stories
Norwegian Cruise Line Returns to Canary Islands
Oceania Cruises Announces 2024 Voyage Collection
NCLH Posts $4 Billion Loss in 2020; 2022 Bookings Look Positive
Regent Seven Seas Cruises Unveils New Shore Excursion Concepts